You are here

Prasanna Alluri, MD, PhD

Chief Resident, Radiation Oncology
Research Fellow, Translational Oncology
University of Michigan
Ann Arbor, Michigan
Conquer Cancer Foundation of ASCO

Current Research

  • Seeking to improve outcomes for patients with advanced, treatment-resistant, estrogen receptor (ER)-positive breast cancers.

  • Laboratory studies are conducted to identify the molecular mechanisms by which mutations in the ER gene cause resistance to ER-directed therapy.

  • The findings of this study may lead to new clinical trials evaluating the efficacy of novel drugs to improve outcomes in patients with advanced ER-positive breast cancer.

Breast cancer is the most commonly diagnosed non-skin cancer and the second leading cause of cancer-related deaths among women in the United States. Approximately 70 percent of all breast cancers express the estrogen receptor (ER) and blocking ER signaling (via endocrine therapies) is an effective strategy for treating these cancers. However, a significant proportion of patients treated with endocrine therapies develop resistance to these drugs and there are currently limited treatment options for these patients.

There is an urgent need to understand why patients develop resistance to endocrine therapies and to develop new treatments to prevent or treat endocrine resistant breast cancers. One established mechanism of resistance to this therapy is a mutation in the estrogen receptor gene, called ESR1.

Dr. Alluri will test a new drug in laboratory models of ER-positve breast cancer that harbor the ESR1 mutation and have become resistsant to targeted therapy. These studies may lead to more personlized treatments for these patients.


Prasanna G. Alluri, MD, PhD is a Chief Resident in Radiation Oncology at the University of Michigan and a Research Fellow in Translational Oncology in the laboratories of Arul Chinnaiyan, MD, PhD and Dan Hayes, MD. His research interests are focused on understanding molecular mechanisms underlying treatment resistance and disease progression in breast cancer. He is currently studying the role of estrogen receptor gene (ESR1) mutations in conferring endocrine therapy resistance in breast cancer and developing new targeting strategies to overcome such resistance. His long term goal is to translate scientific discoveries in the lab into personalized and more effective treatments for patients with breast cancer.

BCRF Investigator Since


Area(s) of Focus